Metastatic Hormone Sensitive Prostate Cancer clinical trials

Explore recruiting metastatic hormone sensitive prostate cancer clinical trials.

Recruiting metastatic hormone sensitive prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Hormone Sensitive Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

One multicenter, randomized, open, phase III clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of metastatic hormone-sensitive prostate cancer with high tumor load.

Czechia, Bulgaria, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer.

Cyprus, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer

Hungary, Spain, Italy, Germany, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281)

Spain, Slovakia, Poland, Belgium, Czechia, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Denmark, Poland, Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

"APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN".

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Hormone Sensitive Prostate Cancer trials by city

Metastatic Hormone Sensitive Prostate Cancer in Toronto Metastatic Hormone Sensitive Prostate Cancer in Vancouver Metastatic Hormone Sensitive Prostate Cancer in Montreal Metastatic Hormone Sensitive Prostate Cancer in Calgary Metastatic Hormone Sensitive Prostate Cancer in Edmonton Metastatic Hormone Sensitive Prostate Cancer in Ottawa Metastatic Hormone Sensitive Prostate Cancer in Winnipeg Metastatic Hormone Sensitive Prostate Cancer in Quebec City Metastatic Hormone Sensitive Prostate Cancer in Hamilton Metastatic Hormone Sensitive Prostate Cancer in Kitchener Metastatic Hormone Sensitive Prostate Cancer in London Metastatic Hormone Sensitive Prostate Cancer in Halifax Metastatic Hormone Sensitive Prostate Cancer in New York Metastatic Hormone Sensitive Prostate Cancer in Los Angeles Metastatic Hormone Sensitive Prostate Cancer in Chicago Metastatic Hormone Sensitive Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease